Where does Artax Biopharma Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Artax Biopharma Inc. ranks #34,327 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Artax Biopharma Inc. hold?

Artax Biopharma Inc. holds 7 US utility patents granted between 2018 and 2025, spanning 2 technology areas.

What is Artax Biopharma Inc.'s Innovation Score?

Artax Biopharma Inc. has an Innovation Score of 33.6 out of 100 (45th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Artax Biopharma Inc.'s patent grant rate increasing or decreasing?

Artax Biopharma Inc.'s recent grant velocity is +400% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Artax Biopharma Inc.'s patents?

Artax Biopharma Inc.'s patents average 19.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Artax Biopharma Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Artax Biopharma Inc.

Q: What technology areas does Artax Biopharma Inc. focus on?

Artax Biopharma Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents. Grants appear in 2 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 2 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Artax ranks #34,327 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 2 technology areas.

#34,327
of 49,997 US assignees by volume: 45th percentile
by Innovation Score (33.6/100): 19.0
avg claims per patent: +400%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R34327 · US Corporation #34,327 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #34,327/49,997
PHOTO-FINISH Ark Biotech
CPC-NARROW A61P · 2 areas
INNOV-THIN 33.6/100
CLAIMS-RICH 19.0 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +400% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ark Biotech Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Artax Biopharma · this assignee

34
3D Lighting… · lowest

7

What this shows Artax's Innovation Score is 33.6/100 (45th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Artax's grants concentrate

Artax Biopharma Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2018. By volume, Artax sits between Ark Biotech Inc. and Asia Pacific Medical Technology Development Company, Ltd.

Artax's three-year grant acceleration

Artax Biopharma Inc. shows 3 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ark Biotech

7
Arqit

7
Arrikto

7
Arrow Fastener

7
Artificial

7
Asco Numatics

7
Asha Medical

7
Asia Pacific Medi…

7
Artax Biopharma ◀

7

What this shows Artax holds 7 patents at rank #34,357, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Artax

By rank, the assignees closest to #34,357 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Artax's primary technology class.

Artax's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 45th percentile higher than 45% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Artax Biopharma Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	14.3%
2020	1	14.3%
2021	1	14.3%
2022	2	28.6%
2023	1	14.3%
2025partial year	1	14.3%

Which technologies does Artax Biopharma Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

C07D - Heterocyclic Compounds 7

Top 2 of 2 technology areas

Where it ranks

Overall rank by patents

#34,327

of 49,997 tracked assignees

Innovation Score

33.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Artax Biopharma Inc.'s patent record in context - here's where to go next.

Artax Biopharma Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #34,327 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Artax Biopharma Inc. against Ark Biotech Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.